Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Community-based follow-up for late patients enrolled in a district-wide programme for antiretroviral therapy in Lusaka, Zambia.

Krebs DW, Chi BH, Mulenga Y, Morris M, Cantrell RA, Mulenga L, Levy J, Sinkala M, Stringer JS.

AIDS Care. 2008 Mar;20(3):311-7. doi: 10.1080/09540120701594776.

PMID:
18351478
2.

How late is too late? Timeliness to scheduled visits as an antiretroviral therapy adherence measure in Nairobi, Kenya and Lusaka, Zambia.

Blacher RJ, Muiruri P, Njobvu L, Mutsotso W, Potter D, Ong'ech J, Mwai P, Degroot A, Zulu I, Bolu O, Stringer J, Kiarie J, Weidle PJ.

AIDS Care. 2010 Nov;22(11):1323-31. doi: 10.1080/09540121003692235.

PMID:
20711886
3.

Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic.

Giordano TP, White AC Jr, Sajja P, Graviss EA, Arduino RC, Adu-Oppong A, Lahart CJ, Visnegarwala F.

J Acquir Immune Defic Syndr. 2003 Apr 1;32(4):399-405.

PMID:
12640198
4.

Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.

Bouhnik AD, Préau M, Vincent E, Carrieri MP, Gallais H, Lepeu G, Gastaut JA, Moatti JP, Spire B; MANIF 2000 Study Group.

Antivir Ther. 2005;10(1):53-61.

PMID:
15751763
5.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
6.
7.

Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.

Bedell R, Heath KV, Hogg RS, Wood E, Press N, Yip B, O'Shaughnessy MV, Montaner JS.

Antivir Ther. 2003 Oct;8(5):379-84.

PMID:
14640384
8.

CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.

McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH.

Clin Infect Dis. 2005 Dec 1;41(11):1662-70. Epub 2005 Oct 19.

PMID:
16267741
9.

Barriers to the care of HIV-infected children in rural Zambia: a cross-sectional analysis.

van Dijk JH, Sutcliffe CG, Munsanje B, Hamangaba F, Thuma PE, Moss WJ.

BMC Infect Dis. 2009 Oct 16;9:169. doi: 10.1186/1471-2334-9-169.

10.

Effectiveness of antiretroviral treatment in a South African program: a cohort study.

Fairall LR, Bachmann MO, Louwagie GM, van Vuuren C, Chikobvu P, Steyn D, Staniland GH, Timmerman V, Msimanga M, Seebregts CJ, Boulle A, Nhiwatiwa R, Bateman ED, Zwarenstein MF, Chapman RD.

Arch Intern Med. 2008 Jan 14;168(1):86-93. doi: 10.1001/archinternmed.2007.10.

PMID:
18195200
11.

When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.

Badri M, Cleary S, Maartens G, Pitt J, Bekker LG, Orrell C, Wood R.

Antivir Ther. 2006;11(1):63-72.

PMID:
16518961
12.
13.

Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire.

Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, Monga B, Maurice C, Nkengasong J, Konan-Koko R, Kadio A, Wiktor S, Lackritz E, Saba J, Chorba T.

AIDS. 2003 Jul;17 Suppl 3:S5-15.

PMID:
14565604
14.

Predictors of failure of first-line antiretroviral therapy in HIV-infected adults: Indian experience.

Rajasekaran S, Jeyaseelan L, Vijila S, Gomathi C, Raja K.

AIDS. 2007 Jul;21 Suppl 4:S47-53.

PMID:
17620752
15.
16.

Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.

Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G.

Ann Intern Med. 2007 Apr 17;146(8):564-73.

PMID:
17438315
17.

Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.

García F, de Lazzari E, Plana M, Castro P, Mestre G, Nomdedeu M, Fumero E, Martínez E, Mallolas J, Blanco JL, Miró JM, Pumarola T, Gallart T, Gatell JM.

J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):702-13.

PMID:
15167289
18.
19.

Defaulters from antiretroviral treatment in Jimma University Specialized Hospital, Southwest Ethiopia.

Deribe K, Hailekiros F, Biadgilign S, Amberbir A, Beyene BK.

Trop Med Int Health. 2008 Mar;13(3):328-33. doi: 10.1111/j.1365-3156.2008.02006.x. Epub 2008 Feb 21.

20.

Self-reported reasons among HIV-infected patients for missing clinic appointments.

Park WB, Kim JY, Kim SH, Kim HB, Kim NJ, Oh MD, Choe KW.

Int J STD AIDS. 2008 Feb;19(2):125-6. doi: 10.1258/ijsa.2007.007101.

PMID:
18334069

Supplemental Content

Support Center